Join Growin Stock Community!

Universe pharmaceuticals inc.UPC.US Overview

US StockHealthcare
(No presentation for UPC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

UPC AI Insights

UPC Overall Performance

UPC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

UPC Recent Performance

-1.10%

Universe pharmaceuticals inc.

0.05%

Avg of Sector

-0.31%

S&P500

UPC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

UPC Key Information

UPC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

UPC Profile

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

Price of UPC

UPC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

UPC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
15.53
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.09
PB Ratio
0.03
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
27.88%
Net Margin
43.14%
Revenue Growth (YoY)
-24.12%
Profit Growth (YoY)
-22.63%
3-Year Revenue Growth
-25.17%
3-Year Profit Growth
-40.81%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
15.53
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.09
PB Ratio
0.03
Price-to-FCF
-
Gross Margin
27.88%
Net Margin
43.14%
Revenue Growth (YoY)
-24.12%
Profit Growth (YoY)
-22.63%
3-Year Revenue Growth
-25.17%
3-Year Profit Growth
-40.81%

  • When is UPC's latest earnings report released?

    The most recent financial report for Universe pharmaceuticals inc. (UPC) covers the period of 2024Q4 and was published on 2024/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating UPC's short-term business performance and financial health. For the latest updates on UPC's earnings releases, visit this page regularly.

  • What is the operating profit of UPC?

    According to the latest financial report, Universe pharmaceuticals inc. (UPC) reported an Operating Profit of -6.28M with an Operating Margin of -61.93% this period, representing a decline of 70.83% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is UPC's revenue growth?

    In the latest financial report, Universe pharmaceuticals inc. (UPC) announced revenue of 10.14M, with a Year-Over-Year growth rate of -26.74%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does UPC have?

    As of the end of the reporting period, Universe pharmaceuticals inc. (UPC) had total debt of 7.73M, with a debt ratio of 0.1. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does UPC have?

    At the end of the period, Universe pharmaceuticals inc. (UPC) held Total Cash and Cash Equivalents of 47.27M, accounting for 0.59 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is UPC's EPS continuing to grow?

    According to the past four quarterly reports, Universe pharmaceuticals inc. (UPC)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of UPC?

    Universe pharmaceuticals inc. (UPC)'s Free Cash Flow (FCF) for the period is -7.37M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 100.14% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.